NEW YORK (GenomeWeb News) – BioTrove said today that it has teamed up with OSI Pharmaceuticals to offer customers a combination of the firm’s drug discovery platforms.
The alliance will offer OSI’s Integrated Lead Discovery Platform with BioTrove’s RapidFire mass spectrometry-based assay development, screening, and analysis services. The OSI platform enables screening of large volumes of compounds against target assays, while the RapidFire platform enables label-free, high-throughput screening using biological substrates to identify active compounds within chemical libraries.
The companies expect that the combined tools will “enable increased research around novel targets for companies who may have crucial insights about disease progression, but do not specialize in large-scale, high-throughput screening internally,” said BioTrove President and CEO Albert Luderer in a statement.
Financial terms of the alliance were not disclosed.